Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9507931 | 0.86 | GRIK1 (0.55) | MAPTGAAPOLBGRIK1ALDH1A1 | |
| SCHEMBL5156571 | 0.84 | SMN1; SMN2 (0.67) | MAPTGRIK1ALDH1A1CYP3A4ALOX15 | |
| SCHEMBL11733765 | 0.82 | SMN1; SMN2 (0.64) | MAPTGAAPOLBALDH1A1KMT2A | |
| SCHEMBL9507967 | 0.82 | MAPT (0.51) | MAPTGAAPOLBGRIK1ALDH1A1 | |
| SCHEMBL10542066 | 0.81 | ALDH1A1 (0.55) | MAPTGAAGRIK1ALDH1A1CYP3A4 | |
| SCHEMBL7974577 | 0.81 | ALDH1A1 (0.55) | MAPTGAAGRIK1ALDH1A1CYP3A4 | |
| SCHEMBL3694733 | 0.80 | MAPT (0.77) | MAPTGAAGRIK1ALDH1A1CYP3A4 | |
| SCHEMBL12703765 | 0.80 | KMT2A (0.61) | MAPTGAAPOLBGRIK1ALDH1A1 | |
| SCHEMBL14574207 | 0.80 | MAPT (0.55) | MAPTGAAGRIK1ALDH1A1CYP3A4 | |
| SCHEMBL6618201 | 0.80 | ALDH1A1 (0.55) | MAPTGAAGRIK1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305652-A2 | Trisubstituted quinazolinone derivatives as vanilloid antagonists | Novartis AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2009-03-26 | — | — | US | disclosed |
| US-20080318940-A1 | Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080318940-A1 | Quinazolinone Derivatives as Vanilloid Antagonists | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| EP-1963283-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007065662-A2 | TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065663-A1 | QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318940-A1 | Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV2 | MAPT 3323/4885GAA 2792/4885POLB 4778/4885 |
| US-20090082365-A1 | Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists | TRPV1, TRPV3, TRPV5 | MAPT 2714/4885GAA 4248/4885POLB 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.